Publications by authors named "Scott C Brun"

Claim this Profile
A
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
D William Cameron, Barbara A da Silva, Jose R Arribas, Robert A Myers, Nicholaos C Bellos, Scott C Brun

J Infect Dis· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
Robert L Murphy, Barbara A da Silva, Charles B Hicks, Joseph J Eron, Roy M Gulick, Scott C Brun

HIV Clin Trials· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
Sarah Palmer, Frank Maldarelli, Ann Wiegand, Barry Bernstein, George J Hanna, Scott C Brun

Proc Natl Acad Sci U S A· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
Daniel Podzamczer, Martin S King, Cheri E Klein, Charles Flexner, Christine Katlama, Scott C Brun

HIV Clin Trials· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.
Cheri Enders Klein, Yi-Lin Chiu, Walid Awni, Tong Zhu, Renee S Heuser, Scott C Brun

J Acquir Immune Defic Syndr· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.
Frank Maldarelli, Sarah Palmer, Martin S King, Ann Wiegand, Michael A Polis, Scott C Brun

PLoS Pathog· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.
Eduardo Sprinz, Andrade J Neto, Eduardo Bargman, Stephen L Green, Michelle P Luo, Scott C Brun

HIV Clin Trials· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
Margaret A Johnson, Joseph C Gathe, Daniel Podzamczer, Jean-Michel Molina, Christian T Naylor, Scott C Brun

J Acquir Immune Defic Syndr· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
Joanna Z Peng, Federico Pulido, Sonja J Kemmis Causemaker, Jianling Li, Alicia Lorenzo, Scott C Brun

J Clin Pharmacol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
Martin S King, Scott C Brun, Dale J Kempf

J Infect Dis· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
Martin S King, Barry M Bernstein, Sharon L Walmsley, Renslow Sherer, Judith Feinberg, Scott C Brun

J Infect Dis· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
Charles Hicks, Martin S King, Roy M Gulick, A Clinton White, Joseph J Eron, Scott C Brun

AIDS· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy.
Aiming Yang, Martin S King, Lixin Han, Jeffrey D Isaacson, Toby Mueller, C Brun Scott

AIDS· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Dale J Kempf, Jeffrey D Isaacson, Martin S King, Scott C Brun, Jacquelyn Sylte

Antivir Ther· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
Constance A Benson, Steven G Deeks, Scott C Brun, Roy M Gulick, Joseph J Eron

J Infect Dis· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis